Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 500-504

  Cutler, Corey ^a   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

allogeneic stem cell transplantation; graft versus host disease; sirolimus

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OVERALL SURVIVAL; PHOTOTHERAPY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VEIN OCCLUSION;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77958553914     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833e5b2e     Document Type: Review

References (30)

1. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72:1924-1929.
2. Hoda D, Pidala J, Salgado-Vila N, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2009 [Epub ahead of print].
3. Ghez D, Rubio MT, Maillard N, et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009; 88:1081-1087.
4. Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:881-885.
5. Jurado M, Vallejo C, Perez-Simon JA, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:701-706.
6. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130:409-417.
7. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:47-55.
8. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109:3108-3114.
9. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115:1098-1105.
10. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112:4425-4431.
11. Furlong T, Kiem HP, Appelbaum FR, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14:531-537.
12. Wolff D, Andree H, Hilgendorf I, et al. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation: timing and conditioning regimen may be crucial. Biol Blood Marrow Transplant 2008; 14:942-943.
13. Koenen H, Michielsen E, Verstappen J, et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation 2003; 75:1581-1590.
14. Nakamura R, Palmer J, Parker P, et al. Improved outcome after reduced intensity allogeneic hematopoietic stem cell transplantation (RI-HCT) for myelodysplastic syndrome (MDS) using tacrolimus/sirolimus-based Gvhd prophylaxis. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2771.
15. Pulsipher MA, Wall DA, Grimley M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009; 147:691-699.
16. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based nonmyeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130:256-264.
17. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100:15113-15118.
18. Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-5774.
19. Alyea EP, Li S, Kim HT, et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:920-926.
20. Ho VT, Aldridge J, Kim HT, et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:844-850.
21. Sandmaier BM, Maris M, Storer B, et al. A randomized 3-arm phase II study to determine the most promising postgrafting immunosuppression for prevention of acute graft-versus-host disease (GVHD) after unrelated donor hema-topoietic cell transplantation (HCT) using nonmyeloablative conditioning for patients with hematologic malignancies: a multi-center trial. Blood (ASH Annual Meeting Abstracts) 2009; 114:348.
22. Snyder DS, Palmer J, Gaal K, et al. Improved outcomes using tacrolimus/ sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 2010; 16:281-286.
23. JohnstonL,FlorekM,ArmstrongR,et al. Sirolimus and mycophenolate mofetil as graft-versus-host disease prophylaxis in myeloablative, matched related donor hematopoietic cell transplantation. Blood (ASH Annual Meeting Abstracts) 2008; 112:4348.
24. Schleuning M, Judith D, Jedlickova Z, et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009; 43:717-723.
25. Al Kadhimi ZS, Gul Z, Lum LG, et al. The combination of tacrolimus (T), sirolimus (S), and rabbit anti-thymocyte globulin (thymoglobulin thymo) to prevent acute graft-vs-host disease (aGVHD) in patients (pts) receiving unrelated hematopoietic stem cell transplantation (UHSCT). Blood (ASH Annual Meeting Abstracts) 2009; 114:2239.
26. von Reyn CL, Ehmann WC, Rybka WB, Claxton DF. Sirolimusinunmanipulated haploidentical cell transplantation. Bone Marrow Transplant 2008; 42:765-766.
27. Peccatori J, Clerici D, Messina C, et al. Rapamycin-based GvHD prophylaxis is effective in T-cell replete unmanipulated haploidentical peripheral stem cell transplantation for advanced haematological malignancies: results in 46 patients. Blood (ASH Annual Meeting Abstracts) 2009; 114:666.
28. Cutler C, Stevenson K, Kim HT, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (in press).
29. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13:82-89.
30. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110:3064-3070.